667, L.P.'s Net Worth

$1.55 Billion

Who is 667, L.P.?

667, L.P. has an estimated net worth of $1.55 Billion. This is based on reported shares across multiple companies, which include SYNAGEVA BIOPHARMA CORP, GENOMIC HEALTH INC, BIOCRYST PHARMACEUTICALS INC, BeiGene, Ltd., IDERA PHARMACEUTICALS, INC., ACADIA PHARMACEUTICALS INC, XOMA Corp, Seagen Inc., INCYTE CORP, Prelude Therapeutics Inc, Kiniksa Pharmaceuticals, Ltd., Zymeworks Inc., IGM Biosciences, Inc., Kodiak Sciences Inc., DBV Technologies S.A., TScan Therapeutics, Inc., Neoleukin Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Talis Biomedical Corp, ALEXION PHARMACEUTICALS, INC., MADRIGAL PHARMACEUTICALS, INC., and Mirati Therapeutics, Inc..

SEC CIK

667, L.P.'s CIK is 0001551139

Past Insider Trading and Trends

2016 was 667, L.P.'s most active year for acquiring shares with 359 total transactions. 667, L.P.'s most active month to acquire stocks was the month of April. 2019 was 667, L.P.'s most active year for disposing of shares, totalling 369 transactions. 667, L.P.'s most active month to dispose stocks was the month of October. 2013 saw 667, L.P. paying a total of $53,699,125,055.99 for 548,093,129 shares, this is the most they've acquired in one year. In 2013 667, L.P. cashed out on 117,349,500 shares for a total of $49,999,570,365.60, their largest year based on trade value.